Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Slightly Bullish +12

Erste Group Bank Has Pessimistic View of BMY FY2027 Earnings

AI-generated analysis

📉 Erste Group Bank analyst H. Engel cut FY2027 EPS estimates for Bristol Myers Squibb to $6.10 from $6.12.

📊 The stock currently holds a consensus 'Hold' rating with an average target price of $61.25 across major banks.

💰 Q1 2026 results showed strong performance with $1.58 EPS, beating the $1.42 consensus estimate.

📈 Revenue for the quarter reached $11.49 billion, representing a 2.6% year-over-year increase.

🏦 Institutional investors increased stakes in Q4, with AQR Capital Management raising its position by 172.6%.

💵 The company declared a quarterly dividend of $0.63 per share, yielding 4.2% annually to shareholders.

📉 Bank of America lowered its price objective to $66.00 while maintaining a 'buy' rating on the stock.

📉 Cantor Fitzgerald restated a neutral rating with a lower target price of $54.00 for the shares.

🏛️ The firm maintains a strong balance sheet with a debt-to-equity ratio of 2.10 and a quick ratio of 1.28.

🧬 Bristol Myers Squibb focuses its pipeline on oncology, hematology, immunology, and cardiovascular diseases.

Bullish Signals
  • Bristol Myers Squibb reported Q1 2026 EPS of $1.58, which significantly topped analyst consensus estimates of $1.42.
  • The company achieved a net margin of 15.01% and a return on equity of 64.87% during the quarter.
  • Quarterly revenue of $11.49 billion exceeded expectations of $10.93 billion, showing growth of 2.6% year-over-year.
  • Major institutional investors including Vanguard Group, State Street Corp, and Geode Capital Management increased their holdings in the fourth quarter.
  • AQR Capital Management aggressively increased its stake by 172.6%, adding over 16 million shares to its portfolio.
  • The company offers a substantial annualized dividend yield of 4.2% with a payout ratio of 70.79%.
Risk Factors
  • Erste Group Bank analyst lowered the FY2027 EPS forecast to $6.10, indicating reduced growth expectations for the coming year.
  • Cantor Fitzgerald set a neutral rating with a target price of $54.00, which is below the current trading price.
  • Bank of America reduced its price objective from $67.00 to $66.00 despite maintaining a buy rating.
Full Analysis
Erste Group Bank analyst H. Engel has lowered its full-year 2027 earnings per share (EPS) forecast for Bristol Myers Squibb to $6.10, down from a previous estimate of $6.12. This adjustment places the company below the broader consensus estimate of $6.34. The report was issued on July 15th, signaling a shift in analyst sentiment regarding future profitability expectations for the biopharmaceutical firm. Recent market activity shows mixed signals from other major financial institutions. While Bank of America maintained a 'buy' rating despite cutting its price target to $66.00, Cantor Fitzgerald set a lower neutral target at $54.00. The stock currently trades with a consensus 'Hold' rating and a target price of $61.25, trading near its 52-week high of $62.89 but well above its 52-week low of $42.52. Fundamental performance remains robust based on the latest quarterly results released on April 30th. Bristol Myers Squibb reported EPS of $1.58, beating analyst expectations of $1.42, with revenue reaching $11.49 billion, a 2.6% increase year-over-year. The company maintains strong financial health with a return on equity of 64.87% and a net margin of 15.01%, while offering an annualized dividend yield of 4.2%. Institutional ownership continues to grow significantly among major asset managers. Vanguard Group, State Street Corp, Geode Capital Management, Norges Bank, and AQR Capital Management all increased their holdings in the fourth quarter. Notably, AQR Capital Management boosted its position by 172.6%, while institutional investors collectively own 76.41% of the company's outstanding shares.